7 September 2023
SHARE NOW
ATE
Cell Therapy
Finance & Investment
Gene Therapy
Regulatory & Standards
Reimbursement
Strategy
Miguel Forte, kicks off this panel session analyzing the retrospect of cell and gene therapy surrounding ideas of best practice, evidence generation for pricing, reimbursement and regulatory approval.
During this session, Miguel Forte, CEO, Kiji Therapeutics and President-Elect, ISCT is joined by Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion, Orchard Therapeutics, Mantej Chhina, Executive Director, Head of Global R&D Regulatory Policy, BioMarin and Julia Djonova, Head of the Advanced Therapy Medicinal Products, Swissmedic.
This Session was recorded at Advanced Therapies Europe 2023.
More like this
Scalable, xeno-free expansion of mesenchymal stem cells in a fixed-bed bioreactor
This case study showcases the successful expansion of mesenchymal stem cells (MSCs) using Rooster Bio’s xeno-free MSC platform in Univercells Technologies’ scale-X fixed-bed bioreactor. The collaboration highlights seamless process transfer, rapid cell attachment, optimized harvesting with high viability (>96%), and robust scalability from R&D to GMP manufacturing. Key innovations include predictive bioprocess monitoring with Scalia Vision and cost-effective solutions for advanced therapy manufacturing.
19 February 2025
Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate
Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
10 January 2025
